Anika Therapeutics, Inc. - ANIK Company Value to Revenue Ratio

Public company logo of Anika (ANIK)

Anika Therapeutics possesses a transparent development plan for joint treatments and strong management in its dialogue with the FDA. The price-to-sales multiple links this success to the brand's authority in regenerative medicine, where non-invasive treatment methods are highly valued. Meanwhile, 1288.83 determines the latest valuation metric as Cheryl Blanshard's team optimizes the portfolio to expand profitable segments.

ANIK Anika Therapeutics, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

ANIK (anikatherapeutics.com): analytical breakdowns and indicator data

- money and cash flow information:
Fundamental valuation:Anika Therapeutics Inc. ANIK
Mass-produced product of Anika Therapeutics

For Anika Therapeutics (ANIK), which operates in the orthopedic pharmaceuticals segment, the EV-to-revenue ratio serves as a measure of the business's market value net of debt. This metric compares total capitalization with sales volume, excluding the impact of leverage, which allows for an assessment of the real efficiency of technology monetization. Amid competition with bioregenerative methods, the stability of this indicator confirms the resilience of current contracts with clinics, while a decline in the ratio could signal a loss of market position.

Competitor analysis for Anika Therapeutics

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|SI-BONE Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Orthofix Medical OFIX|Bioventus Global (BVS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume KIDS (OrthoPediatrics Inc.)|Enterprise Value-to-Revenue Ratio treace.com|Company Value to Revenue Strata Critical Medical Inc (SRTA)|EV/Sales Multiple CARL|RXST - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio clearpointneuro.com CLPT|STXS: Company Value to Revenue Ratio|STIM: Company Value to Revenue|sightsciences.com - Enterprise Value-to-Revenue Coefficient|Orchestra BioMed Inc. (OBIO) - Enterprise Value-to-Revenue Ratio|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio